WARREN YAMASHITA: Open Payments
NPI 1982137691 · TUSTIN, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$807 in 32 payments from 14 companies in 2025. Trend: 2023 $24 · 2024 $465 · 2025 $807
Food & beverage: $807
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $200 |
| ViiV Healthcare Company | 3 | $100 |
| Gilead Sciences, Inc. | 4 | $87 |
| Indivior Inc. | 2 | $59 |
| Sage Therapeutics, LLC | 2 | $56 |
| Braeburn Inc. | 2 | $55 |
| Lilly USA, LLC | 2 | $46 |
| Amgen Inc. | 2 | $46 |
| Madrigal Pharmaceuticals | 1 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $29 |
Products named: MAVYRET, APRETUDE, VRAYLAR, SUBLOCADE, ZURZUVAE, BRIXADI, OTEZLA, REZDIFFRA.
Industry payments across CA — which companies pay providers there.
